OUR EXPERIENCE WITH TOPOTECAN AS SECOND- LINE TREATMENT OF PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER
Objectives: Single agent intravenous Topotecan is an effective treatment for small cell lung cancer /SCLC/ after failure of first- line chemotherapy. The aim of this study was to evaluate the efficacy and toxicity of intravenous Topotecan in recurrent SCCC. Methods: In the period 2008- 2009 seventee...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Peytchinski Publishing,
2010-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objectives: Single agent intravenous Topotecan is an effective treatment for small cell lung cancer /SCLC/ after failure of first- line chemotherapy. The aim of this study was to evaluate the efficacy and toxicity of intravenous Topotecan in recurrent SCCC. Methods: In the period 2008- 2009 seventeen consecutive patients with relapsed SCLC entered the study. The treatment schedule consists of Topotecan 1,5 mg/m2 i.v. for five consecutive days, with repetition every 21 days. Results: Overall response rate was 23,5%. Median survival was 6,4 months. Nausea, vomiting and neutropenia were most common side effects. Conclusion: Intravenous Topotecan is effective as second- line therapy for patients with relapsed SCCC with good tolerability. |
|---|---|
| Item Description: | 10.5272/jimab.1632010_70 1312-773X |